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Effects of Diltiazem on Recurrent Myocardial Infarction in Patients
With Non-Q Wave Myocardial Infarction
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Diltiazem has been reported to reduce the short-term in-hospital
reinfarction rate in patients with a non-Q wave myocardial
infarction. In the long-term Multicenter Diltiaxem Postinfarction
Trial, there were 514 patients with non-Q wave myocardial
infarction; 279 patients were randomized to the placebo group and
235 to the treatment group. The average follow-up period was 25
months. There was no difference in baseline clinical characteris-
tics between the two groups .
Early reinfarction (ss6 months) occurred in 17 patients in the
placebo group and in 2 patients in the diltiazem group (p < 0 .001).
Late reinfarction (>6 months) occurred in 13 patients in the
placebo group and in 14 patients in the diltiazem group (p = NS) .
Initial and reinfarction electrocardiograms (ECOS) were analyzed
by easing a coding system that permitted identification of standard
anatomic areas involved In the infarction process . Thirty-one of
Non-Q wave myocardial infarction occurs in about 25% of
patients admitted to the coronary care unit for myocardial
infarction (1) . There are nearly 40 clinical studies since the
late 1960s comparing the short- or long-term prognosis, or
both, in patients with a Q wave versus a non-Q wave
myocardial infarction (1,2) . Patients with a non-Q wave
myocardial infarction usuziiy have less myocardial necrosis,
better left ventricular junction and fewer acute complica-
tions (1). However, these patients have a higher rate of
reinfarction, more evidence of residual ischemia and a
greater incidence of subsequent coronary bypass surgery
and coronary angioplasty (3-I5).
In an analysis of pooled data of 14 studies on the
incidence of reinfarction after myocardial infarction, Gibson
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the 46 patients bad a localized tararetion ma
!-.at" and reinfarcam
ECG5 . In the early reinfardron group, 10 (17%) of 13 infarctions,
occurred in the same ECG region in which the initial infarction
had occurred ; all 10 were in patients in the paceha group. Among
the 18 patients with late reinfarction, the site of the second
infarction was the same as that of the fast in 9 patients and
differed in 9. There was an difference between ore placebo and
diltiazem groups with respect to Intention of the infinctim .
It is concluded
that 1) diltiscem reduce the early but not the
late rate of reiafarctiea, 2) early remfaretke tends to occur in the
same ECG region as that of the index infarction, and 3) d00azem
may reduce the early reinfarction rue by stabilizing the coronary
lesion that caused the index infarction .
(J An Co!! Cardiel 1992,19,1421-5)
(I) noted that the annual incidence rate of reinfarction was
5 .7% in patients with a Q wave myocardial infarction com-
pared with 15 .7% in those with a non-Q wave infarction . In
addition, the majority of reinfarction after a non.Q wave
myocardial infarction involved the same region as that ofthe
index infarction (16-20). Recurrent infarction after a non-Q
wave infarction has been associated with a deleterious effect
on subsequent left ventricular function and survived (3-14)
.
Current evidence (21) suggests that most ran-Q wave myo-
cordial infarctions represent an "incomplete infarction" due
to spontaneous thromholysis . The higher incidence of rein-
farction after non-Q wave myocardial infarction most fre-
quently represents "completion" of the incomplete infarc-
tion
. The Diltiazem Reinfarction Study (22) showed that
treating patients with a non-Q wave myocardial infarction
with diltiazem reduced the incidence of reinfarction in the
very early (2 to 3 weeks) postinfarction period
.
The purpose of our study was to assess the effects of
diltiazem on the reinfarction and subsequent mortality
rates in patients with an index stun-Q wave myocardial
infarction . We also examined whether the effect of diltiazem
on the reinfarction rate in patients with a non-Q wave
myocardial infarction was uniform over the 25-month
follow-up period and whether diltiazem had different treat-
ment effects on "same location" and "different location"
reinfarction.
0733-1097I9L55 .00
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Methods
Patient selection, The Multicenter Diltiazem Postinfarc-
lion Trial (23) was a multicenter study that enrolled 2 .466
patients of either gender between 25 and 75 years of age,
whose clinical presentation and cardiac-specific enzyme
levels confirmed the diagnosis of acute myocardial infarc-
tion. Electrocardiographic (ECG) changes were not required
as entry criteria . The study (23) tested the hypothesis that
the administration of diltiazem before hospital discharge
after acute myocardial infarction would reduce the subse-
quent mortality rate or the combined end point of cardiac
death and nonfatal reinfarction. Patients were followed up
for 12 to 52 months (average 25). Before enrollment, written
informed consent was obtained from each patient . Details
regarding eligibility, data acquisition and data management
have been presented (23) . Patients were excluded from the
original trial if coronary artery bypass surgery or treatment
with a calcium channel blocker was being considered
. In this
study, we also excluded patients with an abnormal Q wave
on the ECG, including those with Q waves that may have
represented a previous infarction
. We did not exclude any
patient because of a history of
a previous infarction .
The cohort for our analysis included 514 patients experi-
encing a non-Q wave myocardial infarction between Febru-
ary 1, 1983 and June 30, 1986 . Patients were randomized
within 3 to 15 days of infarction to receive diltiazem (60 mg
orally, every 6 h) or placebo for the duration of the study .
The diltiazem group comprised 235 patients and the placebo
group included 279 patients . They were followed up for 12 to
52 months (average 25) .
Electrocardiographic classification
. For each patient, a
composite interpretation of coronary care unit and predis-
charge ECGs was coded according to previously described
criteria (24). For four locations (anterior, lateral, inferior and
posterior), the presence of Q waves, ST segment shifts
(elevation, depression or no change) and T wave inversions
was recorded. For each region, a myocardial infarction
category was determined and for each patient a four-digit
number was generated to permit coding . Three distinct
categories were used to describe non-Q wave infarction :
1) ST segment elevation with T wave inversion ; 2) ST
segment depression with or without T wave inversion ; and
3) the absence of any changes suggestive of ischemia . For
this study, all patients with infarction that could be included
in these three categories in any combination were considered
to have a non-Q infarction. A category of old Q-wave
infarction that required isolated Q waves without accompa-
nying ST segment or T wave changes was specifically
excluded from inclusion in this study .
Data acquisition. The variables obtained for each patient
in the present study included baseline clinical characteris-
tics, follow-up events and clinical data, the initial qualifying
ECG, a follow-up ECG during the same hospital admission
and an ECG taken during the first reinfarction. The ECGs for
both the index myocardial infarction and subsequent rein-
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Table
1. Clinical Characteristics at Study Entry in 514 Patients
With an Index Non-Q Wave Myocardial Infarction
'Pulmonary congestion includes coronary care unit findings ofeither rates
on physical examination or pulmonary congestion en chest X-ray nudy .
farction were obtained in 100% of the patients in our study .
All ECGs for subsequent reinfarction were interpreted with-
out the knowledge of the initial ECG findings .
Included in the baseline clinical characteristics
were
demographic data, admission chest X-ray film or auscutta-
tory findings of pulmonary congestion, or both, left ventric-
ular function and treatment variables at entry into the study .
We compared the baseline data between diltiazem and
placebo groups (Table 1) . The subsequent mortality rate for
each group was also compared (Table 2) . In addition to the
baseline characteristics, two additional data points were
collected and analyzed, namely, the monthly incidence of
reinfarction over the follow-up period and the ECG location
of reinfarction in both the diltiazem and placebo groups .
Definitions. Non-Q wave myocardial infarction. A clini-
cally suspected, creating Itinase (CK) isoenzyme-confirmed
myocardial infarction without diagnostic Q waves or R
wave/S wave > 1 in leads V I and V2 satisfied the criteria for
a non-Q wave myocardial infarction . Pa ients whose ECG
was consistent with a prior Q wave myocardial infarction
and those with left bundle branch block or pacemaker
rhythm on the qualifying or subsequent ECG were excluded .
Table 2. Deaths Among All Patients With Non-Q Wave
Myocardial Infarction and Those With Subsequent Rennfarction
Patients With
All Patients Reinfaretion
in =514) (n=46)'
No . I%) No . (%)
Dihiaiem 23001 Its)
Placebo 32(11)
2(7)
'One patient in the diltiazem group died of metastatic carcinoma of the
colon . In the placebo group. one patient died of advanced metastatic liver
disease and one had a cardiac death as a result of a recurrent myocardial
infarction
.
Dihiezem
(n=235)
Placebo
(n=279)
No . I'/) No . l%)
Clinical presuulelioe
Male gender 181(771 203 (731
Mean age (yrl
58.2 x
10 58 .6
t_ 9
Prior myocardial infarction 42(161 soils)
Mean ejection fraction (%) 54 - 13 52 ± 13
Pulmonary congestion' 75 (33) 115 (43)
Clinical course
Bern-bluckerat discharge 94(40)
I11(4n)
Coronary bypass surgery 21)(9) It (61
Mean creative kinose level 754 t 787 699'_ 630
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Reinfarction . This was defined as a recurrent, clinically
identified event, with myocardial necrosis confirmed by CK
isoenzyme elevation .
Localized ECG changes . These included ST and T wave
changes in at least two consecutive anatomic leads that
permitted the identification of the non-Q wave myocardial
infarction as anterior, lateral, inferior, posterior or a combi-
nation of these regions .
Sam and different ECG locations . A reinfarction was
categorized as occurring in the same location as the index
infarction if the ECG changes on reinfarction involved a
region consistent with identical coronary vascular anatomy .
Inferior, posterior and lateral regions were considered to be
in the same vascular distribution, as were anterior and lateral
regions . A reinfarction was categorized as occurring in a
different location if ECG changes involved a region con-
tent with different coronary vascular anatomy .
A limitation of this linkage concept is that an isolated
lateral infarction is adjacent to ail other regions . This oc-
curred only in one patient with late reinfarction in the
dittiazem group . The index infarction in this patient pro-
duced isolated lateral ST depression and reinfarction caused
ST elevations in the anterior and lateral leads . We classified
this patient's reinfarction as occurring in the same location
as the index infarction ; however the final results would not
have been affected if the infarction had been classified as
occurring in a different location. Two other patients, one in
the placebo group with an early reinfarction and one in the
diltiazem group with a late reinfarction, had isolated lateral
ST changes on their index infarction ECG, but had no other
changes on their reinfarction ECG .
Data analysis. We used the Multicenter Diltiazem Postin-
farclion Trial data base, version 2.0 released on April 16,
1988, for our data analysis. We compared the baseline
clinical characteristics of diltiazem-treated patients with
those of the placebo-treated patients by chi-square test . A
plot of the incidence of reinfarction per month over the
course of the study in the diltiazem and placebo groups
demonstrated a difference in the two groups that exists for
the initial 6 months (Fig. 1) . For the purpose of analysis, we
dichotomized our follow-up period into early (<_6 months)
and late (>6 months) reinfarction . We compared the effects
of diltiazem and placebo on the reinfarction rate and ECG
location of the index infarction and reinfarction in the
dichotomized time periods with use of the chi-square or
Fisher exact test . A two-tailed p value <0,01 was considered
significant.
Results
From the original cohort of 2,466 patients, 514 patients
satisfied our inclusion criteria for non-Q wave myocardial
infarction. Of these, 279 patients were randomized to the
placebo group and 235 patients to the diltiazem group . There
was no significant difference in clinical characteristics be-
tween the two groups (Table I) .
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Figure 1. The monthly occurrence of reinfarction after the index
on-Q wa myocardial infarction . Hatched bras indicate patients
treated with dittiazem, while bas indicate patients given placebo .
Ircidenee of reinfarction. In the 25-month follow-up pe-
riod, there were 46 reinfarctions. The reinfarction rate was
7% for the dittiazem group and 11% for the placebo group
(p = NS). When reinfarction was dichotomized into early
(w6 months) and late (>6 months) reinfarction periods, the
group given dittiazem demonstrated a significant (p < 0 .001)
reduction in the incidence of recurrent reinfarction in the
early (<6 months) postinfarction period (lag . 1). In this early
period, there were 2 reinfarction (0 .6%) in the dittiazem
group compared with 17 (6%) in the placebo group (p =
0.01) . In the late (>6 months) postinfarction period, the
diltiazem and placebo groups experienced 14 (4%) and 13
(3%) episodes of recurrent infarction, respectively (p = NS)
.
Location of reinfarction. Among the 46 patients with
reinfarction, we analyzed the site of reinfarction in the 31
patients who had ECG localization of both the index and the
recurrent infarction (Table 3).
Among the 13 patients with early reinfarction, 10 rein-
farctions (77%) occurred in the same ECG location as that of
the index infarction and all 10 of these were in the placebo
group . Three early reinfacctloas, one in the placebo group,
occurred in a site different from that of the index infarction .
Because so few early reinfarction occurred in the dittiazem
group, it is impossible to draw any conclusion regarding the
role of diltiazem on site of reinfarction.
Of the (S late rein farrtions, 9 occurred at the same and 9
at a different ECG location from that of the index infarction.
Table 3. Electrocardiographic Location of Reinfarction Compared
With That of the Index Infarction in 31 Patients
Diltiazem
Placebo
Site of Early Site of Late
Reinfarction Reinfarction
m=13) to =ttn
Same
Dmu nt Same Did- rent
I 2
7 4
10
0
2 5
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There was no difference between the placebo and diltiazem
groups with respect to site of late reinfarction (Table 3) .
Mortality (Table 2)
. The mortality rate for the entire
cohort with a non-Q wave myocardial infarction aver the
25-month mean follow-up period was 10% in the diltiazem
group and 11% in the placebo group (p = NS) . The impact of
recurrent infarction on the total group with a non-Q wave
infarction was small . There were three subsequent deaths
(one cardiac death) in the 46 patients with reinfarction .
Discussion
Using patients from the Multicenter Diltiazem Postinfarc-
tion Trial, we studied a subset of patients with a non-Q wave
myocardial infarction to examine the effects of diltiazem on
the rate and location of recurrent infarction. Our data show
a reduced incidence of reinfarction in patients with a non-Q
wave infarction, which is limited to the 1st 6 months after the
index infarction . During the Ist 6 months, the placebo group
had an annualized reinfarction rate of 12% in contrast to the
1 .6%a rate in the diltiazem group (p = 0.01) .
Previous morphologic (25) and clinical (21) studies have
shown that non-Q wave myocardial infarction may represent
early spontaneous reperfusion
. This is suggested by the
presence of contraction band necrosis in autopsy studies
(25), a greater prevalence of a patent infarct-related artery,
better left ventricular function and regional perfusion and
greater clinical instability with a larger area of viable myo-
cardium still at jeopardy within the perfusion zone of the
infarct-related vessel (16,25)
. Diltiazem may be beneficial in
this setting because of its ability to reduce vascular spasm
(26-28), and decrease the heart rate and blood pressure and
possibly because of its anliplatelel effect (29), which may
help stabilize the lesion in the infarct-related artery and thus
decrease the early reinfarction rate .
Treatment with diltiazem does not influence the incidence
of late (>6 months) reinfarction. The diltiazem group had a
late reinfarction rate of 4%, which was not statistically
different from the 3% incidence in the placebo group . Late
recurrent myocardial infarction may more often represent
progression of native coronary atherosclerotic disease,
which could account for the lack of efficacy of diltiazem in
decreasing the incidence of late reinfarction . The random
distribution of the location of late as compared with early
reinfarctions also gives credence to this hypothesis .
In addition, early reinfarction tended to occur in the same
ECG region as the index infarction (10 of 13) . as suggested
by previous smaller studies (1,17-20) . However, the number
of patients with reinfarction in our study is small and the
differences cannot be supported by statistical testing . In
contrast, of the 18 late reinfarctions, 9 occurred in the same
and 9 in a different site from that of the index infarction and
the development of reinfarction appears to be a more ran-
dom process than that of early reinfarction .
We did not find that recurren! infarction in patients with
an index non-Q wave myocardial infarction predicted a poor
JACC Vol. 19. No. 7
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outcome . In fact, the mortality rate was relatively modest
.
Over the mean follow-up period of 25 months, one cardiac
death and two noncardiac deaths were reported in the 46
patients with reinfarction .
Limitations. The present study is based on a subgroup
analysis of a larger cohort of patients . Further prospective
studies specifically directed to this question are needed to
confirm our findings.
We presumed that ECG changes reflect infarction in
certain regions of the left ventricle
. There are no data from
our study that correlate the ECG changes with alterations on
a ventriculogram. However, earlier studies (30,31) have
demonstrated a strong correlation between infarct location
and Q and T wave changes and less predictability with ST
changes. Our interpretations are strengthened by the fact
that we are comparing ECGs in the same patients with
recurrent infarction .
Implications for therapy. Our present study is consistent
with the hypothesis that the coronary artery lesion respon-
sible for non-Q wave myocardial infarction remains suscep-
tible for approximately 6 months after the index event .
Diltiazem is effective in protecting patients with such infarc-
tion during this early period . Beyond the initial 6 months, we
are unable to document diltiazem to have any significant
effect in reducing the incidence of reinfarction. Prospective
trials are needed to support what is at best a hypothesis
generated by our observations . However, the present anal-
ysis suggests the utility of diltiazem in the first 6 months after
non-Q wave myocardial infarction . This therapeutic ap-
proach seems reasonable, especially in a patient who has no
pulmonary congestion and is not a candidate for beta-
adienergic blocker therapy .
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